Intas Pharmaceuticals Ltd.
http://www.intaspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intas Pharmaceuticals Ltd.
Asia Deal Watch: Otsuka Gets Japanese Rights To Perception’s Mood Disorder Candidate
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Company Information
- Industry
- Services
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
- Vaccines
-
Drug Delivery
- Controlled Release
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Accord Healthcare Ltd.
- Essential Pharmaceuticals, LLC
- Intas Biopharmaceuticals